APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Drugs

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

Selected research

Market Analysis & Forecast

Global Oncology Drugs Market Analysis and Forecast 2026-2032

20 December 2025212 pages

Choose your research edition.

Industry ResearchOncology Drugs Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Read the full market overview

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

Report Includes

This report presents an overview of global market for Oncology Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oncology Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncology Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oncology Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oncology Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oncology Drugs revenue, projected growth trends, production technology, application and end-user industry.

Oncology Drugs Segment by Company

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen

Sanofi

Bayer

Biogen Idec

Teva

Otsuka

Eisai

Merck KGaA

Gilead Sciences

Oncology Drugs Segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Oncology Drugs Segment by Application

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory or Lung Cancer

Others

Oncology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oncology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oncology Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncology Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chemotherapy Major Player Table 3. Targeted Therapy Major Player Table 4. Immunotherapy (Biologic Therapy) Major Player Table 5. Hormonal Therapy Major Player Table 6. Others Major Player Table 7. Global Oncology Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Blood Cancer Major Player Table 9. Breast Cancer Major Player Table 10. Gastrointestinal Cancer Major Player Table 11. Prostate Cancer Major Player Table 12. Respiratory or Lung Cancer Major Player Table 13. Others Major Player Table 14. Oncology Drugs Industry Trends Table 15. Oncology Drugs Industry Drivers Table 16. Oncology Drugs Industry Opportunities and Challenges Table 17. Oncology Drugs Industry Restraints Table 18. Global Oncology Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Oncology Drugs Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Oncology Drugs Market Share by Region (2021-2026) Table 21. Global Oncology Drugs Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Oncology Drugs Market Share by Region (2027-2032) Table 23. Global Oncology Drugs Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Oncology Drugs Revenue Market Share by Players (2021-2026) Table 25. Global Oncology Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Oncology Drugs Key Players Headquarters & Area Served Table 27. Global Oncology Drugs Players, Product Type & Application Table 28. Global Oncology Drugs Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Oncology Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Oncology Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Oncology Drugs Revenue Market Share by Type (2021-2026) Table 35. Global Oncology Drugs Revenue Market Share by Type (2027-2032) Table 36. Global Oncology Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Oncology Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Oncology Drugs Revenue Market Share by Application (2027-2032) Table 41. Roche Company Information Table 42. Roche Business Overview Table 43. Roche Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Roche Oncology Drugs Product Portfolio Table 45. Roche Recent Development Table 46. Celgene Company Information Table 47. Celgene Business Overview Table 48. Celgene Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Celgene Oncology Drugs Product Portfolio Table 50. Celgene Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novartis Oncology Drugs Product Portfolio Table 55. Novartis Recent Development Table 56. Bristol-Myers Squibb Company Information Table 57. Bristol-Myers Squibb Business Overview Table 58. Bristol-Myers Squibb Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Bristol-Myers Squibb Oncology Drugs Product Portfolio Table 60. Bristol-Myers Squibb Recent Development Table 61. Johnson & Johnson Company Information Table 62. Johnson & Johnson Business Overview Table 63. Johnson & Johnson Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Johnson & Johnson Oncology Drugs Product Portfolio Table 65. Johnson & Johnson Recent Development Table 66. Merck & Co. Company Information Table 67. Merck & Co. Business Overview Table 68. Merck & Co. Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Merck & Co. Oncology Drugs Product Portfolio Table 70. Merck & Co. Recent Development Table 71. AstraZeneca Company Information Table 72. AstraZeneca Business Overview Table 73. AstraZeneca Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. AstraZeneca Oncology Drugs Product Portfolio Table 75. AstraZeneca Recent Development Table 76. Pfizer Company Information Table 77. Pfizer Business Overview Table 78. Pfizer Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Pfizer Oncology Drugs Product Portfolio Table 80. Pfizer Recent Development Table 81. Amgen Company Information Table 82. Amgen Business Overview Table 83. Amgen Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Amgen Oncology Drugs Product Portfolio Table 85. Amgen Recent Development Table 86. Eli Lilly Company Information Table 87. Eli Lilly Business Overview Table 88. Eli Lilly Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Eli Lilly Oncology Drugs Product Portfolio Table 90. Eli Lilly Recent Development Table 91. AbbVie Company Information Table 92. AbbVie Business Overview Table 93. AbbVie Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 94. AbbVie Oncology Drugs Product Portfolio Table 95. AbbVie Recent Development Table 96. Takeda Company Information Table 97. Takeda Business Overview Table 98. Takeda Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 99. Takeda Oncology Drugs Product Portfolio Table 100. Takeda Recent Development Table 101. Astellas Company Information Table 102. Astellas Business Overview Table 103. Astellas Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 104. Astellas Oncology Drugs Product Portfolio Table 105. Astellas Recent Development Table 106. Ipsen Company Information Table 107. Ipsen Business Overview Table 108. Ipsen Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 109. Ipsen Oncology Drugs Product Portfolio Table 110. Ipsen Recent Development Table 111. Sanofi Company Information Table 112. Sanofi Business Overview Table 113. Sanofi Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 114. Sanofi Oncology Drugs Product Portfolio Table 115. Sanofi Recent Development Table 116. Bayer Company Information Table 117. Bayer Business Overview Table 118. Bayer Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 119. Bayer Oncology Drugs Product Portfolio Table 120. Bayer Recent Development Table 121. Biogen Idec Company Information Table 122. Biogen Idec Business Overview Table 123. Biogen Idec Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 124. Biogen Idec Oncology Drugs Product Portfolio Table 125. Biogen Idec Recent Development Table 126. Teva Company Information Table 127. Teva Business Overview Table 128. Teva Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 129. Teva Oncology Drugs Product Portfolio Table 130. Teva Recent Development Table 131. Otsuka Company Information Table 132. Otsuka Business Overview Table 133. Otsuka Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 134. Otsuka Oncology Drugs Product Portfolio Table 135. Otsuka Recent Development Table 136. Eisai Company Information Table 137. Eisai Business Overview Table 138. Eisai Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 139. Eisai Oncology Drugs Product Portfolio Table 140. Eisai Recent Development Table 141. Merck KGaA Company Information Table 142. Merck KGaA Business Overview Table 143. Merck KGaA Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 144. Merck KGaA Oncology Drugs Product Portfolio Table 145. Merck KGaA Recent Development Table 146. Gilead Sciences Company Information Table 147. Gilead Sciences Business Overview Table 148. Gilead Sciences Oncology Drugs Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 149. Gilead Sciences Oncology Drugs Product Portfolio Table 150. Gilead Sciences Recent Development Table 151. North America Oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 152. North America Oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 153. North America Oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Oncology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. North America Oncology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 157. North America Oncology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 158. Europe Oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 159. Europe Oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 160. Europe Oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 161. Europe Oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 162. Europe Oncology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Oncology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 164. Europe Oncology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 165. China Oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 166. China Oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 167. China Oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 168. China Oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 169. Asia Oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 170. Asia Oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 171. Asia Oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 172. Asia Oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Oncology Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Asia Oncology Drugs Revenue by Region (US$ Million) & (2021-2026) Table 175. Asia Oncology Drugs Revenue by Region (US$ Million) & (2027-2032) Table 176. SAMEA Oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 177. SAMEA Oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 178. SAMEA Oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 179. SAMEA Oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 180. SAMEA Oncology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. SAMEA Oncology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 182. SAMEA Oncology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Oncology Drugs Image Figure 2. Global Oncology Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chemotherapy Image Figure 5. Targeted Therapy Image Figure 6. Immunotherapy (Biologic Therapy) Image Figure 7. Hormonal Therapy Image Figure 8. Others Image Figure 9. Global Oncology Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Oncology Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 11. Blood Cancer Image Figure 12. Breast Cancer Image Figure 13. Gastrointestinal Cancer Image Figure 14. Prostate Cancer Image Figure 15. Respiratory or Lung Cancer Image Figure 16. Others Image Figure 17. Global Oncology Drugs Market Size (US$ Million) & (2021-2032) Figure 18. Global Oncology Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Oncology Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Oncology Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Oncology Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Oncology Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Oncology Drugs Revenue Market Share by Type (2021-2032) Figure 25. Global Oncology Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Oncology Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Oncology Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Oncology Drugs Revenue Share by Type (2021-2032) Figure 30. North America Oncology Drugs Revenue Share by Application (2021-2032) Figure 31. North America Oncology Drugs Revenue Share by Country (2021-2032) Figure 32. United States Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Oncology Drugs Revenue Share by Type (2021-2032) Figure 37. Europe Oncology Drugs Revenue Share by Application (2021-2032) Figure 38. Europe Oncology Drugs Revenue Share by Country (2021-2032) Figure 39. Germany Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Oncology Drugs Revenue Share by Type (2021-2032) Figure 49. China Oncology Drugs Revenue Share by Application (2021-2032) Figure 50. Asia Oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Oncology Drugs Revenue Share by Type (2021-2032) Figure 52. Asia Oncology Drugs Revenue Share by Application (2021-2032) Figure 53. Asia Oncology Drugs Revenue Share by Region (2021-2032) Figure 54. Japan Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Oncology Drugs Revenue Share by Type (2021-2032) Figure 62. SAMEA Oncology Drugs Revenue Share by Application (2021-2032) Figure 63. SAMEA Oncology Drugs Revenue Share by Country (2021-2032) Figure 64. Brazil Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others
Applications
  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Respiratory or Lung Cancer
  • Others
Companies covered
  • Roche
  • Celgene
  • Novartis
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck & Co.
  • AstraZeneca
  • Pfizer
  • Amgen
  • Eli Lilly
  • AbbVie
  • Takeda
  • Astellas
  • Ipsen
  • Sanofi
  • Bayer
  • Biogen Idec
  • Teva
  • Otsuka
  • Eisai
  • Merck KGaA
  • Gilead Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oncology Drugs Market by Type
  3. 1.2.1 Global Oncology Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chemotherapy
  5. 1.2.3 Targeted Therapy
  6. 1.2.4 Immunotherapy (Biologic Therapy)
  7. 1.2.5 Hormonal Therapy
  8. 1.2.6 Others
  9. 1.3 Oncology Drugs Market by Application
  10. 1.3.1 Global Oncology Drugs Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Blood Cancer
  12. 1.3.3 Breast Cancer
  13. 1.3.4 Gastrointestinal Cancer
  14. 1.3.5 Prostate Cancer
  15. 1.3.6 Respiratory or Lung Cancer
  16. 1.3.7 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Oncology Drugs Market Dynamics
  1. 2.1 Oncology Drugs Industry Trends
  2. 2.2 Oncology Drugs Industry Drivers
  3. 2.3 Oncology Drugs Industry Opportunities and Challenges
  4. 2.4 Oncology Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oncology Drugs Market Perspective (2021-2032)
  2. 3.2 Global Oncology Drugs Growth Trends by Region
  3. 3.2.1 Global Oncology Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oncology Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Oncology Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oncology Drugs Revenue by Players
  2. 4.1.1 Global Oncology Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Oncology Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oncology Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oncology Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oncology Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Oncology Drugs Players, Product Type & Application
  8. 4.5 Global Oncology Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oncology Drugs Market CR5 and HHI
  11. 4.6.3 2025 Oncology Drugs Tier 1, Tier 2, and Tier 3
5 Oncology Drugs Market Size by Type
  1. 5.1 Global Oncology Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oncology Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Oncology Drugs Revenue Market Share by Type (2021-2032)
6 Oncology Drugs Market Size by Application
  1. 6.1 Global Oncology Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oncology Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Oncology Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche Oncology Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Roche Oncology Drugs Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Celgene
  8. 7.2.1 Celgene Company Information
  9. 7.2.2 Celgene Business Overview
  10. 7.2.3 Celgene Oncology Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Celgene Oncology Drugs Product Portfolio
  12. 7.2.5 Celgene Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Oncology Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Oncology Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Oncology Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Oncology Drugs Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Johnson & Johnson
  26. 7.5.1 Johnson & Johnson Company Information
  27. 7.5.2 Johnson & Johnson Business Overview
  28. 7.5.3 Johnson & Johnson Oncology Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Johnson & Johnson Oncology Drugs Product Portfolio
  30. 7.5.5 Johnson & Johnson Recent Developments
  31. 7.6 Merck & Co.
  32. 7.6.1 Merck & Co. Company Information
  33. 7.6.2 Merck & Co. Business Overview
  34. 7.6.3 Merck & Co. Oncology Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Merck & Co. Oncology Drugs Product Portfolio
  36. 7.6.5 Merck & Co. Recent Developments
  37. 7.7 AstraZeneca
  38. 7.7.1 AstraZeneca Company Information
  39. 7.7.2 AstraZeneca Business Overview
  40. 7.7.3 AstraZeneca Oncology Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AstraZeneca Oncology Drugs Product Portfolio
  42. 7.7.5 AstraZeneca Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Oncology Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Oncology Drugs Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Amgen
  50. 7.9.1 Amgen Company Information
  51. 7.9.2 Amgen Business Overview
  52. 7.9.3 Amgen Oncology Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Amgen Oncology Drugs Product Portfolio
  54. 7.9.5 Amgen Recent Developments
  55. 7.10 Eli Lilly
  56. 7.10.1 Eli Lilly Company Information
  57. 7.10.2 Eli Lilly Business Overview
  58. 7.10.3 Eli Lilly Oncology Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eli Lilly Oncology Drugs Product Portfolio
  60. 7.10.5 Eli Lilly Recent Developments
  61. 7.11 AbbVie
  62. 7.11.1 AbbVie Company Information
  63. 7.11.2 AbbVie Business Overview
  64. 7.11.3 AbbVie Oncology Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 AbbVie Oncology Drugs Product Portfolio
  66. 7.11.5 AbbVie Recent Developments
  67. 7.12 Takeda
  68. 7.12.1 Takeda Company Information
  69. 7.12.2 Takeda Business Overview
  70. 7.12.3 Takeda Oncology Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Takeda Oncology Drugs Product Portfolio
  72. 7.12.5 Takeda Recent Developments
  73. 7.13 Astellas
  74. 7.13.1 Astellas Company Information
  75. 7.13.2 Astellas Business Overview
  76. 7.13.3 Astellas Oncology Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Astellas Oncology Drugs Product Portfolio
  78. 7.13.5 Astellas Recent Developments
  79. 7.14 Ipsen
  80. 7.14.1 Ipsen Company Information
  81. 7.14.2 Ipsen Business Overview
  82. 7.14.3 Ipsen Oncology Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Ipsen Oncology Drugs Product Portfolio
  84. 7.14.5 Ipsen Recent Developments
  85. 7.15 Sanofi
  86. 7.15.1 Sanofi Company Information
  87. 7.15.2 Sanofi Business Overview
  88. 7.15.3 Sanofi Oncology Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Sanofi Oncology Drugs Product Portfolio
  90. 7.15.5 Sanofi Recent Developments
  91. 7.16 Bayer
  92. 7.16.1 Bayer Company Information
  93. 7.16.2 Bayer Business Overview
  94. 7.16.3 Bayer Oncology Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Bayer Oncology Drugs Product Portfolio
  96. 7.16.5 Bayer Recent Developments
  97. 7.17 Biogen Idec
  98. 7.17.1 Biogen Idec Company Information
  99. 7.17.2 Biogen Idec Business Overview
  100. 7.17.3 Biogen Idec Oncology Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Biogen Idec Oncology Drugs Product Portfolio
  102. 7.17.5 Biogen Idec Recent Developments
  103. 7.18 Teva
  104. 7.18.1 Teva Company Information
  105. 7.18.2 Teva Business Overview
  106. 7.18.3 Teva Oncology Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Teva Oncology Drugs Product Portfolio
  108. 7.18.5 Teva Recent Developments
  109. 7.19 Otsuka
  110. 7.19.1 Otsuka Company Information
  111. 7.19.2 Otsuka Business Overview
  112. 7.19.3 Otsuka Oncology Drugs Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Otsuka Oncology Drugs Product Portfolio
  114. 7.19.5 Otsuka Recent Developments
  115. 7.20 Eisai
  116. 7.20.1 Eisai Company Information
  117. 7.20.2 Eisai Business Overview
  118. 7.20.3 Eisai Oncology Drugs Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Eisai Oncology Drugs Product Portfolio
  120. 7.20.5 Eisai Recent Developments
  121. 7.21 Merck KGaA
  122. 7.21.1 Merck KGaA Company Information
  123. 7.21.2 Merck KGaA Business Overview
  124. 7.21.3 Merck KGaA Oncology Drugs Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Merck KGaA Oncology Drugs Product Portfolio
  126. 7.21.5 Merck KGaA Recent Developments
  127. 7.22 Gilead Sciences
  128. 7.22.1 Gilead Sciences Company Information
  129. 7.22.2 Gilead Sciences Business Overview
  130. 7.22.3 Gilead Sciences Oncology Drugs Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Gilead Sciences Oncology Drugs Product Portfolio
  132. 7.22.5 Gilead Sciences Recent Developments
8 North America
  1. 8.1 North America Oncology Drugs Revenue (2021-2032)
  2. 8.2 North America Oncology Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Oncology Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Oncology Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Oncology Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Oncology Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Oncology Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Oncology Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Oncology Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Oncology Drugs Revenue by Country
  11. 8.6.1 North America Oncology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oncology Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Oncology Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oncology Drugs Revenue (2021-2032)
  2. 9.2 Europe Oncology Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oncology Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oncology Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Oncology Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oncology Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oncology Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oncology Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Oncology Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oncology Drugs Revenue by Country
  11. 9.6.1 Europe Oncology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oncology Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oncology Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oncology Drugs Revenue (2021-2032)
  2. 10.2 China Oncology Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Oncology Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Oncology Drugs Revenue by Type (2027-2032)
  5. 10.3 China Oncology Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Oncology Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Oncology Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Oncology Drugs Revenue by Application (2027-2032)
  9. 10.5 China Oncology Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oncology Drugs Revenue (2021-2032)
  2. 11.2 Asia Oncology Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oncology Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oncology Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Oncology Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oncology Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oncology Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oncology Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Oncology Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oncology Drugs Revenue by Country
  11. 11.6.1 Asia Oncology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oncology Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oncology Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oncology Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Oncology Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oncology Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oncology Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oncology Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oncology Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oncology Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oncology Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oncology Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oncology Drugs Revenue by Country
  11. 12.6.1 SAMEA Oncology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oncology Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oncology Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst